Simple Summary Pancreatic cancer is one of the most intractable malignant tumors
worldwide, and is known for its refractory and poor prognosis. Pancreatic ductal …

Purpose Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor
proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells …

KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene
in human pancreatic cancer (∼ 95% of cases). Mutations in KRAS lead to its constitutive …

Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest cancers in oncology
because of its increasing incidence and poor survival rate. More than 90% of PDAC patients …

Systemic modalities are crucial in the management of disseminated malignancies and liquid
tumours. However, patient responses and tolerability to treatment are generally poor and …

Kirsten rat sarcoma (KRAS) is a small GTPase which acts as a molecular switch to regulate
several cell biological processes including cell survival, proliferation, and differentiation …

Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical
efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung …

Although KRAS G12C inhibitors have proven that KRAS is a" druggable" target of cancer,
KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to …

KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer
treatment for patients with KRAS G12C-mutant tumors. However, patients receiving these …

Background In lung cancer, overexpression of nuclear export proteins can result in
inactivation of critical tumor suppressor proteins and cell‐cycle regulators. Selective …